Ception Therapeutics - About the company
Ception Therapeutics is an acquired company based in Malvern (United States), founded in 2004 by Steve Tullman. It operates as a Monoclonal antibody (mAb) for eosinophilic inflammatory conditions.. Ception Therapeutics has raised $77.7M in funding. The company has 478 active competitors, including 168 funded and 111 that have exited. Its top competitors include companies like Alexion, argenx and Septerna.
Company Details
Ception Therapeutics discovers, develops, and commercializes new drugs for inflammatory conditions. It offers Reslizumab (mAb) for eosinophilic inflammatory conditions. It also provides Anti-TNF, a class of small molecule anti-TNF receptor agents with the potential to be orally administered. As of Feb 2010, Ception Therapeutics operates as a subsidiary of Cephalon.
Key Metrics
Founded Year
2004
Location
Malvern, United States
Stage
Acquired
Total Funding
$77.7M in 2 rounds
Latest Funding Round
Investors
Ranked
205th among 478 active competitors
Employee Count
1 - 10 as on Jul 01, 2024
Exit Details
Acquired by Cephalon (Feb 23, 2010)
Legal entities associated with Ception Therapeutics
Ception Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Ception Therapeutics, Inc. CIN: 203908762 , United States, Active | - | - | - |
Ception Therapeutics's acquisition details
Click here to take a look at Ception Therapeutics's acquisition in detail
Sign up to download Ception Therapeutics' company profile
Ception Therapeutics's funding and investors
Ception Therapeutics has raised a total funding of $77.7M over 2 rounds. Its first funding round was on Jan 29, 2007. Its latest funding round was a Series C round on May 31, 2007 for $*****. 1 investor participated in its latest round. Ception Therapeutics has 10 institutional investors.
Here is the list of recent funding rounds of Ception Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 31, 2007 | 7960641 | Series C | 8686490 | 6809658 | 3403716 | 9137599 |
Jan 29, 2007 | 5792018 | Series C | 4087082 | 2341965 | 5104013 |
Access funding benchmarks and valuations. Sign up today!View details of Ception Therapeutics's funding rounds and investors
Ception Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Ception Therapeutics is Steve Tullman.
Here are the details of Ception Therapeutics' key team members:
- Steve Tullman: Former Co-Founder & CEO of Ception Therapeutics and founder of 1 other company.
View details of Ception Therapeutics's Founder profiles and Board Members
Ception Therapeutics' employee count trend
Ception Therapeutics has 1 - 10 employees as of Jul 24. Here is Ception Therapeutics's employee count trend over the years:
Uncover Ception Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Ception Therapeutics's Competitors and alternates
Top competitors of Ception Therapeutics include Alexion, argenx and Septerna. Here is the list of Top 10 competitors of Ception Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Alexion 1992, Zurich (Switzerland), Acquired | Developer of therapies for patients with devastating and rare diseases | $133M | 79/100 | |
2nd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 74/100 | ||
3rd | Septerna 2020, San Bruno (United States), Public | Developer of GPCR drug discovery platform for multiple diseases | $250M | 71/100 | |
4th | Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders | $69.7M | 68/100 | ||
5th | Developer of drugs for anti-cancer and anti-inflammatory diseases | $160M | 67/100 | ||
6th | Halozyme 1999, San Diego (United States), Public | Developer of drug delivery technologies for the treatment of various diseases | - | 67/100 | |
7th | ABL Bio 2016, Seongnam-si (South Korea), Public | Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases | $65M | 67/100 | |
8th |  Upstream Bio 2021, Waltham (United States), Public | Developer of therapeutics for allergic and inflammatory diseases | $400M | 66/100 | |
9th |  Ventyx Biosciences 2018, Encinitas (United States), Acquired | Developer of therapeutics to treat autoimmune diseases | $165M | 66/100 | |
10th |  Evommune 2020, Sacramento (United States), Public | Developer of therapeutic options for chronic inflammatory disorders | $276M | 66/100 | |
205th | Ception Therapeutics 2004, Malvern (United States), Acquired | Monoclonal antibody (mAb) for eosinophilic inflammatory conditions. | $77.7M | 35/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Ception Therapeutics's competitors? Click here to see the top ones
Ception Therapeutics's Investments and acquisitions
Ception Therapeutics has made no investments or acquisitions yet.
Reports related to Ception Therapeutics
Here is the latest report on Ception Therapeutics's sector:
News related to Ception Therapeutics
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Ception Therapeutics
Explore our recently published companies
- Bahar-Bardawil - Unfunded company
- Nexa Banking - Charlottesville based, Unfunded company
- Northwest Missouri Credit Union - Blair based, 1904 founded, Unfunded company
- Pinellas Credit Union - United States based, Unfunded company
- BizReply - Unfunded company
- dM Solutions Pvt.Ltd - India based, Unfunded company
